Results 11 to 20 of about 21,169 (256)

Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA) [PDF]

, 2013
The aim of this study was to identify potential ligands of PSMA suitable for further development as novel PSMA-targeted peptides using phage display technology. The human PSMA protein was immobilized as a target followed by incubation with a 15-mer phage
A Ghosh, AC Pawlyk, AM Quinn, CW Diehnelt, D Hessels, D Shen, DB Sodee, Duanwen Shen, E Basch, F Yi, Fei Xie, GA Lazar, H Liu, H Liu, H-S Lim, HD Agnew, IM Thompson, Irina U. Agoulnik, J Yu, JA Arter, JR Mesters, JR Newton, KA Noren, MI Davis, MI Milowsky, MJ Morris, MJ Morris, MJ Roobol, NH Bander, RK Nam, S Aggarwal, S Kim, S Minner, SE Lupold, SM Hillier, SR Banerjee, SR Banerjee, SR Banerjee, SR Banerjee, SS Chang, SZ Li, TJ Wigle, V Humblet, W. Barry Edwards, Y Chen, Y Chen, Y Chen, Z Xiao, ZY Zhu   +48 more
core   +11 more sources

Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement

European Journal of Hybrid Imaging, 2023
Rationale Prostate cancer treatment response may be automatically quantified using a molecular imaging analysis platform targeting prostate-specific membrane antigen (PSMA).
Sai Duriseti, Gholam Berenji, Sonny Tsai, Matthew Rettig, Nicholas G. Nickols   +4 more
doaj   +1 more source

Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer [PDF]

, 2020
Background Several scan parameters for PET imaging with F-18-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide administration on lesion ...
Achten, Eric, De Man, Kathia, De Vos, Filip, Kersemans, Ken, Ost, Piet, Piron, Sarah, Schelfhout, Vanessa, Van Laeken, Nick   +7 more
core   +2 more sources

Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer [PDF]

Xin yixue, 2022
The incidence of prostate cancer ranks second among male cancer patients in the world. Its morbidity and mortality have been rapidly increasing in recent years.
Hu Siqi, Zhang Yong
doaj   +1 more source

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues

Current Oncology, 2023
Theranostics (therapy + diagnosis) targeting prostate-specific membrane antigen (PSMA) is an emerging therapeutic modality that could alter treatment strategies for prostate cancer.
Seiji Hoshi, Kei Yaginuma, Satoru Meguro, Akifumi Onagi, Kanako Matsuoka, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Motohide Uemura, Yoshiyuki Kojima   +11 more
doaj   +1 more source

Prostate-Specific Membrane Antigen (PSMA) PET: A Counterpart to Prostate MRI

Seminars in Roentgenology, 2021
Abstract Prostate cancer is projected to remain the second leading cause of cancer-related death in men in the United States in 2021[1]. Traditionally, initial staging and post-treatment surveillance require a variety of imaging exams, from bone scan and CT to MRI, however conventional imaging is limited by low sensitivity[2-4].
Christine Chen, Daniel J Margolis
openaire   +2 more sources

Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer [PDF]

Prostate Cancer and Prostatic Diseases, 2000
Radioimmunoscintigraphy using a radio-labelled antibody to prostate-specific membrane antigen (PSMA) has growing applications as a means of tissue-specific imaging based on functional characteristics and complements traditional staging investigations. Clinical applications in men with carcinoma of the prostate are being refined, and this study reports ...
M R, Feneley, H, Jan, M, Granowska, S J, Mather, D, Ellison, J, Glass, M, Coptcoat, R S, Kirby, C, Ogden, R T D, Oliver, D F, Badenoch, F I, Chinegwundoh, V H, Nargund, A M I, Paris, K E, Britton   +14 more
openaire   +2 more sources

Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors

Scientific Reports, 2021
Prostate cancer cells are characterized by a remarkably low proliferative rate and the production of high levels of prostate-specific proteases. Protein-based toxins are attractive candidates for prostate cancer therapy because they kill cells via ...
O. C. Rogers, D. M. Rosen, L. Antony, H. M. Harper, D. Das, X. Yang, I. Minn, R. C. Mease, M. G. Pomper, S. R. Denmeade   +9 more
doaj   +1 more source

Laser-activated nanoparticles for ultrasound/photoacoustic imaging-guided prostate cancer treatment

Frontiers in Bioengineering and Biotechnology, 2023
Prostate cancer (PCa) is the most common malignant tumor in men. Prostate-specific membrane antigen (PSMA), which is overexpressed on the surface of Prostate cancer cells, may serve as a potential therapeutic target.
Linkang Xiao, Linkang Xiao, Yunfang Wu, Yunfang Wu, Junyong Dai, Junyong Dai, Weili Zhang, Yang Cao   +7 more
doaj   +1 more source

Advances in targeted Alpha therapy for prostate cancer [PDF]

, 2019
BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G, Gerritsen, W, Gschwend, JE, Hacker, M, Lewington, V, O'Sullivan, JM, Oya, M, Pacilio, M, Parker, C, Sartor, O, Shore, N, Targeted Alpha Therapy Prostate Working Group   +11 more
core   +2 more sources